2:31 PM
 | 
Sep 13, 2018
 |  BC Extra  |  Company News

Boehringer adds to immuno-oncology pipeline with ViraTherapeutics acquisition

Boehringer Ingelheim GmbH (Ingelheim, Germany) exercised an option to acquire oncolytic virus company ViraTherapeutics GmbH (Innsbruck, Austria). Boehringer gained the option under a 2016 deal to jointly develop ViraTherapeutics' oncolytic virus therapy platform and its lead candidate, VSV-GP.

ViraTherapeutics is developing a chimeric oncolytic virus...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >